Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...
Semaglutide use in patients with Type 2 diabetes was associated with reduced postoperative complications after 90 days, according to a study in the March 2025 i ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Hosted on MSN4h
On the rebound: What are the long-term risks of Ozempic?Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback